Subscribe

Higher-Dose Daunorubicin Is Effective in Patients with AML Who Harbor FLT3-ITD Mutations

Conference Correspondent - EHA 2016 Conference

The NCRI AML17 trial compared 2 doses of daunorubicin, 90 mg/m2 (DA90) and 60 mg/m2 (DA60), in the first course of chemotherapy for patients with acute myeloid leukemia (AML). Preliminary findings showed no efficacy benefit for the 90-mg/m2 dose of daunorubicin and a higher rate of early mortality. The goal of this study was to learn if induction with high-dose daunorubicin improves overall survival (OS) in any cytogenetic or genetic subgroup of patients with AML between the ages of 18 and 60 years.1

Between September 2011 and October 2013, 1206 patients were randomized 1:1 to DA90 or DA60 (days 1, 3, and 5) in course 1, then daunorubicin at a dose of 50 mg/m2 (days 1, 3, and 5) in course 2. Ara-C was dosed at 100 mg/m2 on days 1 to 10 (course 1) and days 1 to 8 (course 2). Patients’ median age was 53 years (range, 16-72 years); 54% were male; 84% had de novo AML, 10% secondary, and 6% high-risk myelodysplastic syndromes. Ten percent of patients had favorable cytogenetics, 72% intermediate, and 18% adverse.

Overall, 60-day mortality remained higher with DA90 (10% vs 5%; P = 0.002) and 3-year OS did not differ, suggesting that DA90 is not associated with an OS benefit. However, analysis stratified by FLT3-ITD showed significant heterogeneity. In ITD wild-type patients, OS outcomes were not affected (51% vs 49%; P = 0.3). However, in ITD-mutant patients, an OS benefit was observed (54% vs 34%; P = 0.03). Sixty-day mortality was not different (7% vs 6%; P = 0.8).

These results indicate a potential role for DA90 in patients with FLT3-ITD mutations. In theory, DA90 could complement use of FLT3 inhibitors in these patients, but this decision would require early knowledge of mutation status. Delivery of the escalated daunorubicin dose could also be considered in the second induction course.




  1. Russell N, et al. EHA 2016. Abstract S808.
Related Items
Valuable New Prognostic Scoring System in Patients with CML Receiving Nilotinib as Initial Treatment
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Ibrutinib Results in Robust Clinical Activity and Survival Outcomes in Difficult-to-Treat CLL Populations
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Acalabrutinib, a Second-Generation BTK Inhibitor, Is Active in Previously Untreated CLL
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
CD19 CAR T Cells Induce Potent Responses and Control CNS Leukemia in Relapsed ALL
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Overall Survival Benefit in Relapsed and Refractory B-Cell ALL Patients Receiving Inotuzumab Ozogamicin
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Outcomes Associated with Conventional Salvage Therapy in Patients with Refractory or Relapsed AML and IDH1/IDH2 Mutations
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Response-Adapted Sequential Azacitidine and Intensive Chemotherapy Is Effective in Patients Aged >60 Years with Newly Diagnosed AML
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem-Cell Transplantation for De Novo ALL in Adults
Conference Correspondent published on June 10, 2016 in EHA 2016 Conference
Venetoclax Is Safe and Effective When Combined with Rituximab in Relapsed CLL
Conference Correspondent published on June 9, 2016 in EHA 2016 Conference
Last modified: June 12, 2016
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology